TrovaGene (NASDAQ:TROV) announced its earnings results on Tuesday, May 7th. The medical research company reported ($1.02) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.07) by $0.05, Fidelity Earnings reports. The company had revenue of $0.16 million during the quarter. TrovaGene had a negative net margin of 3,540.91% and a negative return on equity of 121.65%.
TROV traded up $0.05 during trading on Friday, hitting $2.88. 53,187 shares of the company traded hands, compared to its average volume of 752,323. The firm has a market cap of $14.18 million, a P/E ratio of -0.35 and a beta of 0.74. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.76 and a current ratio of 3.76. TrovaGene has a one year low of $2.52 and a one year high of $20.16.
Several analysts have recently commented on the stock. Maxim Group set a $8.00 target price on shares of TrovaGene and gave the company a “buy” rating in a report on Thursday, May 23rd. Noble Financial set a $23.00 target price on shares of TrovaGene and gave the company a “buy” rating in a report on Friday, May 24th. Zacks Investment Research downgraded shares of TrovaGene from a “buy” rating to a “hold” rating in a report on Thursday, May 9th. Finally, ValuEngine downgraded shares of TrovaGene from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $19.63.
Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.
Recommended Story: Risk Tolerance
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.